Covalent Molecular Probes for Class A G Protein-Coupled Receptors: Advances and Applications

ACS Chemical Biology

Volumn 10, Issue 6, 2015, Pages 1376-1386

  Weichert, Dietmar ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; CROSS LINKING REAGENT; FLUORESCENT DYE; LIGAND; MOLECULAR PROBE; PROTEIN BINDING;

ARTICLE; COVALENT BOND; CROSS LINKING; CRYSTAL STRUCTURE; MOLECULAR PROBE; PHARMACOPHORE; PHOTOACTIVATION; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; X RAY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; BINDING SITES; CROSS-LINKING REAGENTS; FLUORESCENT DYES; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR PROBES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84935034113     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00070     Document Type: Article

References (100)

1. Filmore, D. (2004) Its a GPCR world Mod. Drug Discovery 7, 24-26
2. Rosenbaum, D. M., Rasmussen, S. G., and Kobilka, B. K. (2009) The structure and function of G-protein-coupled receptors Nature 459, 356-363
3. Ciruela, F., Jacobson, K. A., and Fernández-Dueñas, V. (2014) Portraying G protein-coupled receptors with fluorescent ligands ACS Chem. Biol. 9, 1918-1928
4. Hiller, C., Kuhhorn, J., and Gmeiner, P. (2013) Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands J. Med. Chem. 56, 6542-6559
5. Takemori, A. E. and Portoghese, P. S. (1985) Affinity Labels for Opioid Receptors Annu. Rev. Pharmacol. Toxicol. 25, 193-223
6. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor Science 289, 739-745
7. Choe, H. W., Kim, Y. J., Park, J. H., Morizumi, T., Pai, E. F., Krauss, N., Hofmann, K. P., Scheerer, P., and Ernst, O. P. (2011) Crystal structure of metarhodopsin II Nature 471, 651-655
8. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., and Stevens, R. C. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 318, 1258-1265
9. Shonberg, J., Kling, R. C., Gmeiner, P., and Löber, S. GPCR crystal structures: Medicinal chemistry in the pocket. Bioorg. Med. Chem. 2014, DOI: 10.1016/j.bmc.2014.12.034.
10. Rasmussen, S. G., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T., Lyons, J. A., Caffrey, M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K., and Kobilka, B. K. (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex Nature 477, 549-555
11. Granier, S. and Kobilka, B. (2011) A new era of GPCR structural and chemical biology Nat. Chem. Biol. 8, 670-673
12. Rosenbaum, D. M., Zhang, C., Lyons, J. A., Holl, R., Aragao, D., Arlow, D. H., Rasmussen, S. G., Choi, H. J., Devree, B. T., Sunahara, R. K., Chae, P. S., Gellman, S. H., Dror, R. O., Shaw, D. E., Weis, W. I., Caffrey, M., Gmeiner, P., and Kobilka, B. K. (2011) Structure and function of an irreversible agonist-beta(2) adrenoceptor complex Nature 469, 236-240
13. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., and Granier, S. (2012) Crystal structure of the mu-opioid receptor bound to a morphinan antagonist Nature 485, 321-326
14. Weichert, D., Kruse, A. C., Manglik, A., Hiller, C., Zhang, C., Hübner, H., Kobilka, B. K., and Gmeiner, P. (2014) Covalent agonists for studying G protein-coupled receptor activation Proc. Natl. Acad. Sci. U.S.A. 111, 10744-10748
15. Dohlman, H. G., Caron, M. G., Strader, C. D., Amlayki, M., and Lefkowitz, R. J. (1988) Identification and sequence of a binding site peptide of the beta2-adrenergic receptor Biochemistry 27, 1813-1817
16. Spalding, T. A., Birdsall, N. J., Curtis, C. A., and Hulme, E. C. (1994) Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors J. Biol. Chem. 269, 4092-4097
17. Pei, Y., Mercier, R. W., Anday, J. K., Thakur, G. A., Zvonok, A. M., Hurst, D., Reggio, P. H., Janero, D. R., and Makriyannis, A. (2008) Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation Chem. Biol. (Cambridge, MA, U. S.) 15, 1207-1219
18. Marjamaki, A., Pihlavisto, M., Cockcroft, V., Heinonen, P., Savola, J.-M., and Scheinin, M. (1998) Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human α2A-adrenergic receptor Mol. Pharmacol. 53, 370-376
19. Morey, T. E., Belardinelli, L., and Dennis, D. M. (1998) Validation of Furchgotts method to determine agonist-dependent A1-adenosine receptor reserve in guinea-pig atrium Br. J. Pharmacol. 123, 1425-1433
20. Furchgott, R. F. and Bursztyn, P. (1967) Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasymthetic receptors Ann. N.Y. Acad. Sci. 144, 882-899
21. Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hubner, H., Pardon, E., Valant, C., Sexton, P. M., Christopoulos, A., Felder, C. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., and Kobilka, B. K. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 504, 101-106
22. Buck, E. and Wells, J. A. (2005) Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor Proc. Natl. Acad. Sci. U.S.A. 102, 2719-2724
23. Buck, E., Bourne, H., and Wells, J. A. (2005) Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor J. Biol. Chem. 280, 4009-4012
24. Ballesteros, J. A. and Weinstein, H. (1992) Analysis and refinement of criteria for predicting the structure and relative orientations of transmembranal helical domains Biophys. J. 62, 107-109
25. Simon, E. J., Hiller, J. M., and Edelman, I. (1973) Stereospecific binding of the potent narcotic analgesic [3H]etorphine to rat-brain homogenate Proc. Natl. Acad. Sci. U.S.A. 70, 1947-1949
26. Gaibelet, G., Capeyrou, R., Dietrich, G., and Emorine, L. J. (1997) Identification in the μ-opioid receptor of cysteine residues responsible for inactivation of ligand binding by thiol alkylating and reducing agents FEBS Lett. 408, 135-140
27. Shirasu, N. and Shimohigashi, Y. (2001) Discriminative disulfide-bonding affinity labeling of opioid receptor subtypes J. Biochem. Biophys. Methods 49, 587-606
28. Isozaki, K., Fukahori, H., Honda, T., Shirasu, N., Okada, K., Nose, T., Sakaguchi, K., and Shimohigashi, Y. (2004) Site-directed affinity-labeling of delta opioid receptors by SNpys-containing enkephalin and dynorphin analogues Lett. Pept. Sci. 10, 511-522
29. Isozaki, K., Fukahori, H., Okada, K., Shirasu, N., Honda, T., Nose, T., Sakaguchi, K., Costa, T., and Shimohigashi, Y. (2003) Specific affinity labeling of Cys60 in the δ opioid receptor by Npys-containing dynorphin A analog Pept. Sci. 40, 273-276
30. Yan, F., Bikbulatov, R. V., Mocanu, V., Dicheva, N., Parker, C. E., Wetsel, W. C., Mosier, P. D., Westkaemper, R. B., Allen, J. A., Zjawiony, J. K., and Roth, B. L. (2009) Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor Biochemistry 48, 6898-6908
31. Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., Pascal, M., and Herbert, J. M. (2000) Identification and biological activity of the active metabolite of clopidogrel Thromb. Haemostasis 84, 891-896
32. Zhang, K., Zhang, J., Gao, Z.-G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paoletta, S., Kiselev, E., Lu, W., Fenalti, G., Zhang, W., Muller, C. E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K. A., Stevens, R. C., Wu, B., and Zhao, Q. (2014) Structure of the human P2Y12 receptor in complex with an antithrombotic drug Nature 509, 115-118
33. Algaier, I., Jakubowski, J. A., Asai, F., and Von KU Gelgen, I. (2008) Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor J. Thromb. Haemost. 6, 1908-1914
34. Doorn, J. A. and Petersen, D. R. (2002) Covalent Modification of Amino Acid Nucleophiles by the Lipid Peroxidation Products 4-Hydroxy-2-nonenal and 4-Oxo-2-nonenal Chem. Res. Toxicol. 15, 1445-1450
35. Jöst, C., Nitsche, C., Scholz, T., Roux, L., and Klein, C. D. (2014) Promiscuity and selectivity in covalent enzyme inhibition: A systematic study of electrophilic fragments J. Med. Chem. 57, 7590-7599
36. Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., and Taunton, J. (2012) Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Nat. Chem. Biol. 8, 471-476
37. Portoghese, P. S., Larson, D. L., Sayre, L. M., Fries, D. S., Smith, A. D., and Takemori, A. E. (1980) A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities J. Med. Chem. 23, 233-234
38. Chen, C., Yin, J., de Riel, J. K., DesJarlais, R. L., Raveglia, L. F., Zhu, J., and Liu-Chen, L.-Y. (1996) Determination of the amino acid residue involved in [3H]β-funaltrexamine covalent binding in the cloned rat μ opioid receptor J. Biol. Chem. 271, 21422-21429
39. Moynihan, H. A., Derrick, I., Broadbear, J. H., Greedy, B. M., Aceto, M. D., Harris, L. S., Purington, L. C. S., Thomas, M. P., Woods, J. H., Traynor, J. R., Husbands, S. M., and Lewis, J. W. (2012) Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects J. Med. Chem. 55, 9868-9874
40. Nijmeijer, S., E, H., Schultes, S., vand de Stolpe, A. C., Lusnik, V., de Graaf, C., Wijtmans, M., Haaksma, E. E. J., Esch, I. J.P., Stachurski, K., Vischer, H. F., and Leurs, R. (2013) Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98 of the human H4 receptor Br. J. Pharmacol. 170, 89-100
41. Surgand, J.-S., Rodrigo, J., Kellenberger, E., and Rognan, D. (2005) A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors Proteins: Struct. Funct. Bioinf. 62, 509-538
42. Kusiak, J. W., Pitha, J., and Piascik, M. T. (1989) Interaction of a chemically reactive prazosin analog with alpha-1 adrenoceptors of rat tissues J. Pharm. Exp. Ther. 249, 70-77
43. Griffin, M. T., Thomas, E. A., and Ehlert, F. J. (1993) Kinetics of activation and in vivo muscarinic receptor binding of N-(2-bromoethyl)-4-piperidinyl diphenylacetate: an analog of 4-DAMP mustard J. Pharm. Exp. Ther. 266, 301-305
44. Robinson, D. A., Taylor, J. G., and Young, J. M. (1975) The irreversible binding of acetylcholine mustard to muscarinic receptors in intestinal smuooth muscle of the guinea-pig Br. J. Pharmacol. 53, 363-370
45. Vogel, W. K., Peterson, G. L., Broderick, D. J., Mosser, V. A., and Schimerlik, M. I. (1999) Double mutant cycle analysis of aspartate 69, 97, and 103 to asparagine mutants in the m2 muscarinic acetylcholine receptor Arch. Biochem. Biophys. 361, 283-294
46. Steyaert, J. and Kobilka, B. K. (2011) Nanobody stabilization of G protein-coupled receptor conformational states Curr. Opin. Struct. Biol. 21, 567-572
47. Gill, E. W. and Rang, H. P. (1966) An alkylating derivative of benzilylcholine with specific and long-lasting parasympatholytic activity Mol. Pharmacol. 2, 284-297
48. Young, J. M., Hiley, R., and Burgen, A. S. (1972) Homologues of benzilylcholine mustard J. Pharm. Pharmacol. 24, 950-954
49. Ehlert, F. J. and Griffin, M. T. (1998) The use of irreversible ligands to inactivate receptor subtypes: 4-DAMP mustard and muscarinic receptors in smooth muscle Life Sci. 62, 1659-1664
50. Ehlert, F. J., Jenden, D. J., and Ringdahl, B. (1984) An alkylating derivative of oxotremorine interacts irreversibly with the muscarinic receptor Life Sci. 34, 985-991
51. Ringdahl, B., Mellin, C., Ehlert, F. J., Roch, M., Rice, K. M., and Jenden, D. J. (1990) Tertiary (2-haloethyl)amine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride J. Med. Chem. 33, 281-286
52. Cornett, L. E. and Norris, J. S. (1986) Affinity labeling of the DDT1MF-2 cell α1-adrenergic receptor with [3H]phenoxybenzamine Biochem. Pharmacol. 35, 1663-1669
53. Timmermans, P. B. M. W. M., Thoolen, M. J. M. C., Mathy, M. J., Wilfert, B., de Jong, A., and van Zwieten, P. A. (1985) Effects of the irreversible alpha-adrenoceptor antagonists phenoxybenzamine and benextramine on the effectiveness of nifedipine in inhibiting alpha1- and alpha2-adrenoceptor mediated vasoconstriction in pithed rats Arch. Pharmacol. 329, 404-413
54. Frang, H., Cockcroft, V., Karskela, T., Scheinin, M., and Marjamäki, A. (2001) Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors J. Biol. Chem. 276, 31279-31284
55. Portoghese, P. S., Larson, D. L., Jiang, J. B., Caruso, T. P., and Takemori, A. E. (1979) Synthesis and pharmacologic characterization of an alkylating analog chlornaltrexamine, of naltrexone with ultralong-lasting narcotic antagonist properties J. Med. Chem. 22, 168-173
56. Baraldi, P. G., Cacciari, B., Moro, S., Romagnoli, R., Ji, X.-d., Jacobson, K. A., Gessi, S., Borea, P. A., and Spalluto, G. (2001) Fluorosulfonyl- and bis-(β-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies J. Med. Chem. 44, 2735-2742
57. Docherty, J. R. and ORourke, M. (1997) The α-adrenoceptor-mediated actions of chloroethylclonidine Vascul. Pharmacol. 28, 197-201
58. Javitch, J. A., Fu, D., and Chen, J. (1995) Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice Biochemistry 34, 16433-16439
59. Winkler, J. D., Thermos, K., and Weiss, B. (1987) Differential effects of fluphenazine-N-mustard, on calmodulin activity and on D1 and D2 dopaminergic responses Psychopharmacology 92, 285-291
60. Cross, A. J., Waddington, J. L., and Ross, S. T. (1983) Irreversible interaction of β-haloalkylamine derivatives with dopamine D1 and D2 receptors Life Sci. 32, 2733-2740
61. Neumeyer, J. L., Law, S. J., Baldessarini, R. J., and Kula, N. S. (1980) Aporphines. 30. (-)-N(2-chloroethyl)-10,11-dihydroxynor-aporphine (chloroethylnorapomorphine), a novel irreversible dopamine receptor antagonist J. Med. Chem. 23, 594-595
62. Emerit, M. B., Gozlan, H., Hall, M. D., and Marquet, A. (1985) Irreversible blockade of central 5-HT binding sites by 8-methoxy-2′-chloro-PAT Biochem. Pharmacol. 34, 883-892
63. Wong, R. and Dolman, S. J. (2007) Isothiocyanates from Tosyl Chloride Mediated Decomposition of in Situ Generated Dithiocarbamic Acid Salts J. Org. Chem. 72, 3969-3971
64. Burke, T. R., Bajwa, B. S., Jacobson, A. E., Rice, K. C., Streaty, R. A., and Klee, W. A. (1984) Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for.mu. or.delta. opiate receptors J. Med. Chem. 27, 1570-1574
65. Davie, B. J., Valant, C., White, J. M., Sexton, P. M., Capuano, B., Christopoulos, A., and Scammells, P. J. (2014) Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M1 muscarinic acetylcholine receptor J. Med. Chem. 57, 5405-5418
66. Mercier, R. W., Pei, Y., Pandarinathan, L., Janero, D. R., Zhang, J., and Makriyannis, A. (2010) hCB2 Ligand-interaction landscape: Cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation Chem. Biol. (Cambridge, MA, U. S.) 17, 1132-1142
67. Szymanski, D. W., Papanastasiou, M., Melchior, K., Zvonok, N., Mercier, R. W., Janero, D. R., Thakur, G. A., Cha, S., Wu, B., Karger, B., and Makriyannis, A. (2011) Mass spectrometry-based proteomics of human cannabinoid receptor 2: Covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation J. Proteome Res. 10, 4789-4798
68. Rice, K. C., Jacobson, A. E., Burke, T. R., Bajwa, B. S., Streaty, R. A., and Klee, W. A. (1983) Irreversible ligands with high selectivity toward delta and mu opiate receptors Science 220, 314-316
69. Burke, T. R., Jr., Jacobson, A. E., Rice, K. C., Silverton, J. V., Simonds, W. F., Streaty, R. A., and Klee, W. A. (1986) Probes for narcotic receptor mediated phenomena. 12. cis-(+)-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for δ opioid receptors. Synthesis, absolute configuration, and receptor enantioselectivity J. Med. Chem. 29, 1087-1093
70. Portoghese, P. S., Sultana, M., and Takemori, A. E. (1990) Naltrindole-5′-isothiocyanate: a nonequilibrium, highly selective δ-opioid receptor antagonist J. Med. Chem. 33, 1547-1548
71. De Costa, B. R., Rothman, R. B., Bykov, V., Jacobson, A. E., and Rice, K. C. (1989) Selective and enantiospecific acylation of κ-opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide. Demonstration of κ receptor heterogeneity J. Med. Chem. 32, 281-283
72. Baldessarini, R. J., Kula, N. S., Campbell, A., Bakthavachalam, V., Yuan, J., and Neumeyer, J. L. (1992) Prolonged D2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain Mol. Pharmacol. 42, 856-863
73. Stiles, G. L. and Jacobson, K. A. (1988) High affinity acylating antagonists for the A1 adenosine receptor: identification of binding subunit Mol. Pharmacol. 34, 724-728
74. Ji, X.-d., Gallo-Rodriguez, C., and Jacobson, K. A. (1994) A selective agonist affinity label for A3 adenosine receptors Biochem. Biophys. Res. Commun. 203, 570-576
75. Jacobson, K. A., Barone, S., Kammula, U., and Stiles, G. L. (1989) Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors J. Med. Chem. 32, 1043-1051
76. Atlas, D. and Steer, M. L. (1982) Clonidine p-isothiocyanate, an affinity label for alpha 2-adrenergic receptors on human platelets Proc. Natl. Acad. Sci. U. S. A. 79, 1378-1382
77. Tsotinis, A., Afroudakis, P. A., Davidson, K., Prashar, A., Smith, A. D., and Sugden, D. (2007) Design, synthesis, and melatoninergic activity of new azido- and isothiocyanato-substituted indoles J. Med. Chem. 50, 6436-6440
78. Baumgold, J., Karton, Y., Malka, N., and Jacobson, K. A. (1992) High affinity acylating antagonists for muscarinic receptors Life Sci. 51, 345-351
79. Newman, A. H., Covington, J., Oleshansky, M., Jackson, B. W., Weissman, B. A., Leader, H., and Chiang, P. K. (1990) Aprophit: An irreversible antagonist for muscarinic receptors Biochem. Pharmacol. 40, 1357-1364
80. Kung, M.-P., Mu, M., Zhuang, Z.-P., and Kung, H. F. (1995) NCS-MPP (4-(2′-methoxyphenyl)-1-[2′-(N-2′-pyridyl)-p-isothiocyanobenzamido]ethylpiperazine): a high affinity and irreversible 5-HT1A receptor ligand Life Sci. 58, 177-186
81. Tahtaoui, C., Balestre, M. N., Klotz, P., Rognan, D., Barberis, C., Mouillac, B., and Hibert, M. (2003) Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors J. Biol. Chem. 278, 40010-40019
82. Shannon, D. A. and Weerapana, E. (2015) Covalent protein modification: the current landscape of residue-specific electrophiles Curr. Opin. Chem. Biol. 24, 18-26
83. Xiang, Z., Ren, H., Hu, Y. S., Coin, I., Wei, J., Cang, H., and Wang, L. (2013) Adding an unnatural covalent bond to proteins through proximity-enhanced bioreactivity Nat. Methods. 10, 885-888
84. Pitha, J., Zjawiony, J., Nasrin, N., Lefkowitz, R. J., and Caron, M. G. (1980) Potent beta-adrenergic antagonist possessing chemically reactive group Life Sci. 27, 1791-1798
85. Homburger, V., Gozlan, H., Bouhelal, R., Lucas, M., and Bockaert, J. (1985) Irreversible blockade of β-adrenergic receptors with a bromoacetyl derivative of pindolol Naunyn-Schmiedebergs Arch. Pharmacol. 328, 279-287
86. Dickinson, K. E., Heald, S. L., Jeffs, P. W., Lefkowitz, R. J., and Caron, M. G. (1985) Covalent labeling of the beta-adrenergic ligand-binding site with para-(bromoacetamidyl)benzylcarazolol. A highly potent beta-adrenergic affinity label Mol. Pharmacol. 27, 499-506
87. Baker, S. P., Liptak, A., and Pitha, J. (1985) Irreversible inactivation of the β-adrenoreceptor by a partial agonist. Evidence for selective loss of the agonist high affinity binding sites J. Biol. Chem. 260, 15820-15828
88. Milecki, J., Baker, S. P., Standifer, K. M., Ishizu, T., Chida, Y., Kusiak, J. W., and Pitha, J. (1987) Carbostyril derivatives having potent β-adrenergic agonist properties J. Med. Chem. 30, 1563-1566
89. Standifer, K. M., Pitha, J., and Baker, S. P. (1989) Carbostyril-based beta-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro Naunyn-Schmiedebergs Arch. Pharmacol. 339, 129-137
90. Deyrup, M. D., Greco, P. G., Otero, D. H., Dennis, D. M., Gelband, C. H., and Baker, S. P. (1998) Irreversible binding of a carbostyril-based agonist and antagonist to the β-adrenoceptor in DDT1MF-2 cells and rat aorta Br. J. Pharmacol. 124, 165-175
91. Witt-Enderby, P. A., Chu, G.-H., Gillen, M. L., and Li, P.-K. (1997) Development of a high-affinity ligand that binds rrreversibly to Mel1b melatonin receptors J. Med. Chem. 40, 4195-4198
92. Newman, A. H. (1991) Irreversible ligands as probes for drug receptors NIDA Res. Monogr. 112, 256-283
93. Bartuschat, A. L., Schellhorn, T., Hübner, H., Gmeiner, P., and Heinrich, M. R. (2015) Fluoro-substituted phenylazocarboxamides: Dopaminergic behavior and N-arylating properties for irreversible binding, Bioorg. Med. Chem., 14, DOI: 10.1016/j.bmc.2014.12.012.
94. Dong, J., Krasnova, L., Finn, M. G., and Sharpless, K. B. (2014) Sulfur(VI) fluoride exchange (SuFEx): Another good reaction for click chemistry Angew. Chem., Int. Ed. 53, 9430-9448
95. Beauglehole, A. R., Baker, S. P., and Scammells, P. J. (2002) New irreversible adenosine A1 antagonists based on FSCPX Bioorg. Med. Chem. Lett. 12, 3179-3182
96. Beauglehole, A. R., Baker, S. P., and Scammells, P. J. (2000) Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the A1-adenosine receptor J. Med. Chem. 43, 4973-4980
97. Srinivas, M., Shryock, J. C., Scammells, P. J., Ruble, J., Baker, S. P., and Belardinelli, L. (1996) A novel irreversible antagonist of the A1-adenosine receptor Mol. Pharmacol. 50, 196-205
98. Le Bourdonnec, B., Kouhen, R. E., Lunzer, M. M., Law, P. Y., Loh, H. H., and Portoghese, P. S. (2000) Reporter affinity labels: An o-phthalaldehyde derivative of β-naltrexamine as a fluorogenic ligand for opioid receptors J. Med. Chem. 43, 2489-2492
99. McCurdy, C. R., Le Bourdonnec, B., Metzger, T. G., Kouhen, R. E., Zhang, Y., Law, P. Y., and Portoghese, P. S. (2002) Naphthalene dicarboxaldehyde as an electrophilic fluorogenic moiety for affinity labeling: application to opioid receptor affinity labels with greatly improved fluorogenic properties J. Med. Chem. 45, 2887-2890
100. Portoghese, P. S., El Kouhen, R., Law, P. Y., Loh, H. H., and Le Bourdonnec, B. (2001) Affinity labels as tools for the identification of opioid receptor recognition sites Farmaco 56, 191-196